Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.

Background: In the long-term extension study of the ERASURE and FIXTURE trials, the efficacy of secukinumab (a fully human anti-interleukin-17A monoclonal antibody) was demonstrated to have been maintained through to year 3 of treatment in moderate-to-severe plaque psoriasis.

Objectives: To assess the efficacy and safety of secukinumab through to year 5 of treatment in moderate-to-severe plaque psoriasis.

Methods: Responders with ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) from two core trials - ERASURE and FIXTURE - were randomized 2 : 1 at year 1 (end of core trials) to either the same dose (300 or 150 mg, continuous treatment) or placebo (treatment withdrawal) every 4 weeks, until year 3 or relapse (> 50% reduction in maximal PASI from core study baseline).

Conjugate heat transfer study of various cooling structures and sensitivity analysis of overall cooling effectiveness.

The conjugate heat transfer of a turbine blade is influenced by several factors. To analyze the influence of each factor, the published one-dimensional conjugate heat transfer model was improved through theoretical analysis in this study. An overall cooling effectiveness equation containing three dimensionless parameters (adiabatic film cooling effectiveness η, Biot number on the mainstream side Bi, and ratio between the heat transfer coefficients of the external and internal walls h/h) was obtained.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.

Background: Obesity is a common comorbidity of psoriasis and can attenuate response to biologic treatment.

Objectives: To investigate the efficacy, safety and tolerability of secukinumab 300 mg every 2 weeks (Q2W) vs. secukinumab 300 mg every 4 weeks (Q4W) in patients with a higher bodyweight.

Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control.

This paper describes the innovative pediatric development strategy of secukinumab in psoriasis. Initially, this pediatric development had been planned early during the adult development program. This is common for most development programs as it is required by law in major regions worldwide.

Experimental Investigation on Velocity and Temperature Field in a Rotating Non-isothermal Turbulent Boundary Layer using Hot-wire.

This experiment measured the instantaneous temperature and velocity field synchronously in non-isothermal turbulent boundary layer in a rotating straight channel with a parallel-array hot-wire probe. The Reynolds number based on the bulk mean velocity (U) and hydraulic diameter (D) is 19000, and the rotation numbers are 0, 0.07, 0.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.

Background: Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment.

Objective: Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects with palmoplantar psoriasis.

Methods: In this double-blinded, randomized controlled trial, 205 subjects were randomized 1:1:1 to secukinumab 300 mg, 150 mg, or placebo.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.

Background: Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis.

Objective: To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks.

Methods: Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

Background: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study).

Objective: We sought to directly compare efficacy and safety of secukinumab versus ustekinumab.

Methods: In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 to subcutaneous injection of secukinumab 300 mg or ustekinumab per label.

Area level deprivation and drinking patterns among adolescents.

Objective: To assess relationships between area level deprivation and drinking patterns among adolescents.

Method: This study uses data from the national New Zealand Alcohol Survey 2004 comprising 1828, age range 12-19 years. A multilevel linear regression was conducted using NZDep2001 (a composite deprivation measure) as the exposure and alcohol use (quantity and frequency) as outcome.